These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2069 related items for PubMed ID: 18679072

  • 1. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 2. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H, Tatsch F.
    Ann Hepatol; 2012 Jul; 11(1):52-61. PubMed ID: 22166561
    [Abstract] [Full Text] [Related]

  • 3. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 5. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [Abstract] [Full Text] [Related]

  • 6. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
    Husa P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Urbanek P.
    Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
    [Abstract] [Full Text] [Related]

  • 8. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC, Tran TT, Poordad FF.
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [Abstract] [Full Text] [Related]

  • 9. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 10. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May 15; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.
    New Microbiol; 2005 Jan 15; 28(1):13-21. PubMed ID: 15782622
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM.
    J Clin Virol; 2007 Jan 15; 38(1):32-8. PubMed ID: 17064957
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A, Austrian Hepatitis Study Group.
    J Hepatol; 2006 Feb 15; 44(2):275-82. PubMed ID: 16338019
    [Abstract] [Full Text] [Related]

  • 14. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Gut; 2015 Feb 15; 64(2):303-11. PubMed ID: 24747867
    [Abstract] [Full Text] [Related]

  • 15. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 Feb 15; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 16. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB, Atabay A, Akin MS, Yalaki S.
    Eur J Gastroenterol Hepatol; 2013 Sep 15; 25(9):1082-5. PubMed ID: 23524524
    [Abstract] [Full Text] [Related]

  • 17. Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
    Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Enomoto N, Inao M, Tanaka A, Kaito M, Imazeki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, Izumi N, Kudo M, RETRY Study Group.
    Dig Dis; 2012 Sep 15; 30(6):554-60. PubMed ID: 23258094
    [Abstract] [Full Text] [Related]

  • 18. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N, Sprinzl MF, Zimmermann T, Wörns MA, Zimmerer T, Galle PR, Stremmel W, Eisenbach C, Stein K, Antoni C, Schattenberg JM, Pathil A.
    BMC Gastroenterol; 2015 Aug 04; 15():97. PubMed ID: 26239732
    [Abstract] [Full Text] [Related]

  • 19. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G, ANRS HC16 GAMMATRI Trial Group.
    J Gastroenterol Hepatol; 2013 Feb 04; 28(2):329-34. PubMed ID: 23190183
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Husa P.
    Eur J Gastroenterol Hepatol; 2011 Nov 04; 23(11):1004-10. PubMed ID: 21904204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 104.